These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27266953)

  • 1. Value of expanding HCV screening and treatment policies in the United States.
    Linthicum MT; Gonzalez YS; Mulligan K; Moreno GA; Dreyfus D; Juday T; Marx SE; Lakdawalla DN; Edlin BR; Brookmeyer R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP227-35. PubMed ID: 27266953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
    Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
    Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
    J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH; Ward JW; Sherman KE
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations.
    Moreno GA; Wang A; Sánchez González Y; Díaz Espinosa O; Vania DK; Edlin BR; Brookmeyer R
    Value Health; 2017 Jun; 20(6):736-744. PubMed ID: 28577690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
    Deuffic-Burban S; Mathurin P; Pol S; Larsen C; Roudot-Thoraval F; Desenclos JC; Dhumeaux D; Yazdanpanah Y
    Gut; 2012 Feb; 61(2):290-6. PubMed ID: 21930731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.
    McEwan P; Kim R; Yuan Y
    Appl Health Econ Health Policy; 2013 Feb; 11(1):53-63. PubMed ID: 23329380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
    Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
    Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
    Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
    Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The wider public health value of HCV treatment accrued by liver transplant recipients.
    Jena AB; Stevens W; Gonzalez YS; Marx SE; Juday T; Lakdawalla DN; Philipson TJ
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP212-9. PubMed ID: 27266951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.